Present Status and Prospects of Drug Delivery Approaches: Managing the Blood-Brain Barrier Treatment in Brain Tumors

Résumé fourni par la source

Developing effective treatments for CNS disorders remains a formidable challenge due to the existence of multiple physiological barriers, primarily the bloodbrain barrier (BBB), which severely restricts medication invasion into the brain and consequently compromises therapeutic efficacy. Effective brain-targeted drug delivery, especially to diseased cells, requires overcoming these barriers to develop promising therapies for brain disorders. Current research focuses on diverse nanocarrier structures and surface-engineered, site-specific novel transporters to improve effectiveness and minimize the untoward effects of brain therapy. These methods aim to bypass the BBB or enhance its permeability, thereby increasing the absorption of medication in the brain. However, the effectiveness of innovative transporter systems is influenced by physiological factors such as Efflux-mediated excretion, Brain protein coating, Persistence, Cytotoxicity of the nanocarriers, and patient-specific factors. Thus, understanding the composition of the brain, the BBB, and related features is crucial for developing effective carrier systems. Additionally, alternative routes like direct nasalto-brain drug transfer proposal promise revenue to contact the brain without the BBB barrier. This chapter discusses the characteristics of several biological barriers, as well as the BBB and BCSFB (blood-cerebrospinal fluid barrier), in drug treatment and the mechanisms of drug transport that cross the BBB. It additionally explores innovative approaches for brain-targeted drug delivery, as well as dendrimers, nanogels, inorganic nanoparticles, liposomes, polymeric nanoparticles, nanoemulsions, quantum dots, lipidic nanoparticles, and intranasal drug delivery. Features disturbing the drugtargeting efficacy of these innovative transporter systems are also illustrated.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.